Across TCGA pan-cancer cohorts, RPN1 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated RPN1 data layer compared with 20 for mass-spec protein and 6 for mutation status.
The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher RPN1 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated RPN1 expression acts as an unfavorable survival marker, although some lineages such as HNSC and LUAD show a favorable association.
CCRCC, HNSC, and LUAD are the cancer types where RPN1 mass-spec protein most reproducibly stratifies survival.